ATE514090T1 - Verwendung des proteins satb2 als marker zur unterscheidung kolorektaler karzinome von anderen krebserkrankungen - Google Patents

Verwendung des proteins satb2 als marker zur unterscheidung kolorektaler karzinome von anderen krebserkrankungen

Info

Publication number
ATE514090T1
ATE514090T1 AT10158956T AT10158956T ATE514090T1 AT E514090 T1 ATE514090 T1 AT E514090T1 AT 10158956 T AT10158956 T AT 10158956T AT 10158956 T AT10158956 T AT 10158956T AT E514090 T1 ATE514090 T1 AT E514090T1
Authority
AT
Austria
Prior art keywords
marker
colorectal carcinoma
cancer diseases
differentiate
satb2
Prior art date
Application number
AT10158956T
Other languages
German (de)
English (en)
Inventor
Mathias Uhlen
Fredrik Ponten
Original Assignee
Atlas Antibodies Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atlas Antibodies Ab filed Critical Atlas Antibodies Ab
Application granted granted Critical
Publication of ATE514090T1 publication Critical patent/ATE514090T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57535—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT10158956T 2006-06-02 2007-06-04 Verwendung des proteins satb2 als marker zur unterscheidung kolorektaler karzinome von anderen krebserkrankungen ATE514090T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06114954A EP1862803A1 (en) 2006-06-02 2006-06-02 Use of protein SATB2 as a marker for colorectal cancer
US81661306P 2006-06-27 2006-06-27

Publications (1)

Publication Number Publication Date
ATE514090T1 true ATE514090T1 (de) 2011-07-15

Family

ID=36968849

Family Applications (2)

Application Number Title Priority Date Filing Date
AT10158956T ATE514090T1 (de) 2006-06-02 2007-06-04 Verwendung des proteins satb2 als marker zur unterscheidung kolorektaler karzinome von anderen krebserkrankungen
AT07725799T ATE513216T1 (de) 2006-06-02 2007-06-04 Verwendung des proteins satb2 als prognostischer marker für kolorektalkarzinome

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT07725799T ATE513216T1 (de) 2006-06-02 2007-06-04 Verwendung des proteins satb2 als prognostischer marker für kolorektalkarzinome

Country Status (11)

Country Link
US (3) US8067190B2 (enExample)
EP (3) EP1862803A1 (enExample)
JP (2) JP4990970B2 (enExample)
CN (2) CN103293307B (enExample)
AT (2) ATE514090T1 (enExample)
AU (1) AU2007256391B2 (enExample)
CA (1) CA2653952A1 (enExample)
DK (2) DK2211180T3 (enExample)
ES (1) ES2367412T3 (enExample)
PL (1) PL2211180T3 (enExample)
WO (1) WO2007140966A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100662821B1 (ko) * 2006-04-05 2006-12-28 유니트마 주식회사 레시피언트 블록 성형용 몰드 및 이를 이용한 레시피언트블록의 제조방법
EP1862803A1 (en) 2006-06-02 2007-12-05 Atlas Antibodies AB Use of protein SATB2 as a marker for colorectal cancer
EP2107375A1 (en) * 2008-03-31 2009-10-07 Atlas Antibodies AB Uses of WARS protein in cancer prognostics
EP2172477A1 (en) * 2008-10-06 2010-04-07 Atlas Antibodies AB Epitopes derived from SATB2 and uses thereof
EP2396657B1 (en) * 2009-02-16 2013-11-13 Atlas Antibodies AB Rbm3 as a marker for malignant melanoma prognosis
US11506663B2 (en) 2014-05-13 2022-11-22 Vastcon Methionine aminopeptidase overexpression in the peripheral blood and peripheral blood mononuclear cells is a marker for colorectal cancer screening, diagnosis and prognosis
US11326210B2 (en) * 2015-01-30 2022-05-10 Glax Llc Compositions and methods for monitoring, diagnosis, prognosis, detection, and treatment of cancer
US20160258438A1 (en) * 2015-03-05 2016-09-08 Regal Beloit America, Inc. Assembly, blower and associated method
US20180282815A1 (en) * 2015-04-29 2018-10-04 Geneoscopy, Llc Colorectal cancer screening method and device
AU2017348369B2 (en) 2016-10-27 2023-09-28 Geneoscopy, Inc. Detection method
CN106841131A (zh) * 2016-12-29 2017-06-13 上海交通大学 一种基于角蛋白自荧光作为预测检测肿瘤的生物标志物的检测方法及其应用
AU2019276577B2 (en) 2018-06-01 2025-09-11 Geneoscopy, Inc. Detection method
EP3833779A4 (en) * 2018-08-08 2022-05-11 Indian Institute Of Science Education And Research COMBINED EXPRESSION PATTERN OF SATB FAMILY CHROMATIN ORGANIZERS AS AN IMPROVED BIOMARKER TOOL FOR CANCER PREDICTION
US12435335B2 (en) 2022-06-06 2025-10-07 Cornell University Promoting nutrient absorption through the colon

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9828840D0 (en) 1998-12-30 1999-02-17 Univ Nottingham Trent Prostate cancer associated genes and their products
DE19932688B4 (de) 1999-07-13 2009-10-08 Scil Proteins Gmbh Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen
US20030129207A1 (en) * 2001-08-21 2003-07-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of colon cancer
US20090215711A1 (en) * 2004-04-30 2009-08-27 Sagres Discovery, Inc. Novel compositions and methods in cancer
DE102004037860A1 (de) * 2004-08-04 2006-03-16 Friedrich-Alexander-Universität Erlangen-Nürnberg Turmormarker zur Diagnose von Karzinomen und/oder davon abstammender Metastasen
EP2177614B1 (en) * 2005-05-02 2014-12-31 Toray Industries, Inc. Composition and method for diagnosing esophageal cancer and metastasis of esophageal cancer
GB2435882A (en) 2006-03-09 2007-09-12 Bioinvent Int Ab Detection and treatment of mantle cell lymphoma
EP1862803A1 (en) 2006-06-02 2007-12-05 Atlas Antibodies AB Use of protein SATB2 as a marker for colorectal cancer

Also Published As

Publication number Publication date
DK2211180T3 (da) 2011-09-26
CA2653952A1 (en) 2007-12-13
JP4990970B2 (ja) 2012-08-01
PL2211180T3 (pl) 2011-11-30
ATE513216T1 (de) 2011-07-15
US8465934B2 (en) 2013-06-18
EP2211180A1 (en) 2010-07-28
JP5301630B2 (ja) 2013-09-25
EP1862803A1 (en) 2007-12-05
EP2024747B1 (en) 2011-06-15
JP2012073260A (ja) 2012-04-12
US8241859B2 (en) 2012-08-14
EP2211180B1 (en) 2011-06-22
AU2007256391A1 (en) 2007-12-13
CN103293307A (zh) 2013-09-11
US20090220975A1 (en) 2009-09-03
CN101460850A (zh) 2009-06-17
EP2024747A1 (en) 2009-02-18
WO2007140966A1 (en) 2007-12-13
US20120028836A1 (en) 2012-02-02
CN103293307B (zh) 2016-03-23
US8067190B2 (en) 2011-11-29
AU2007256391B2 (en) 2011-05-19
ES2367412T3 (es) 2011-11-03
JP2009539082A (ja) 2009-11-12
US20120270956A1 (en) 2012-10-25
DK2024747T3 (da) 2011-09-19

Similar Documents

Publication Publication Date Title
ATE514090T1 (de) Verwendung des proteins satb2 als marker zur unterscheidung kolorektaler karzinome von anderen krebserkrankungen
WO2011119934A3 (en) Methods and materials for detecting colorectal neoplasm
ATE450547T1 (de) Eml4-alk-fusionsgen
ATE527385T1 (de) Mit tumoren assoziierte genetische variationen
MX2007010349A (es) Composiciones y metodos para clasificar muestras biologicas.
WO2010045318A3 (en) Gene and gene expressed protein targets depicting biomarker patterns and signature sets by tumor type
WO2006110581A3 (en) Cancer-related genes
WO2007149476A3 (en) Assays for non-apoptotic cell death and uses thereof
GB0607943D0 (en) Biomarkers for chronic transplant dysfunction
WO2012154567A3 (en) Human invasion signature for prognosis of metastatic risk
CY1112553T1 (el) Ανοσοπροσδιορισμοι υψηλης ευαισθησιας και κιτια για τον προσδιορισμο πεπτιδιων και πρωτεϊνων βιολογικου ενδιαφεροντος
ATE431426T1 (de) Verfahren zur identifizierung von lrrk2 interagierenden molekülen und zur reinigung von lrrk2
ATE491809T1 (de) Amplifikation von dna-fragmenten
WO2007112054A3 (en) Facilitation of translocation of molecules through the gastrointestinal tract
ATE430936T1 (de) Verwendung von cyfra 21-1 und osteopontin als marker für kolorektalkarzinome
WO2006034278A3 (en) Methods and compositions for detecting cancer using components of the u2 spliceosomal particle
DE602007008872D1 (de) Mikrowellengestützte deglycosylierung von proteinen zur molekulargewichtsbestimmung durch massenspektrometrie
ATE468535T1 (de) Verwendung von nnmt als marker für lungenkrebs
WO2007087263A3 (en) Human zip1, zinc and citrate for prostate cancer screening
WO2008108873A3 (en) Molecular biosensors for detecting macromolecules and other analytes
ATE412182T1 (de) Verwendung der proteine proteinase 3 (prn3) und leukozyten elastatse inhibitor (ileu) als marker für kolorektale karzinome
ATE462803T1 (de) Kit und verfahren zum nachweis von urothelkarzinom
WO2009019366A3 (fr) Procede de dosage de l'aminoacylase 1 pour le diagnostic in vitro du cancer colorectal
ATE353544T1 (de) Verwendung des proteins masp als marker für kolorektale karzinome
WO2006110587A3 (en) Ddr2 in cancer diagnosis, detection and treatment

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties